Back

Lundbeck to present 401-participant MSA trial data at MDS 2026

Verifying
  • Lundbeck will present movement-disorder research at MDS 2026 in Seoul from 4-8 October.
  • 401 participants enrolled in the ongoing Phase III MASCOT trial of amlenetug for MSA.
  • MASCOT results are expected in Q3 2027 after a 72-week double-blind treatment period.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.